Animal & Veterinary

Enrofloxacin for Poultry

Withdrawal of Approval of Bayer Corporation’s
New Animal Drug Application (NADA) 140-828 (Baytril)
Docket No. 2000N-1571 *

The Center for Veterinary Medicine (CVM) proposed the withdrawal of fluoroquinolones in poultry water. The Center determined that the use of fluoroquinolones in poultry:

  • caused the development of fluoroquinolone-resistant Campylobacter species in poultry,
  • that these fluoroquinolone-resistant organisms are transferred to humans and cause the development of fluoroquinolone-resistant Campylobacter in humans,
  • and fluoroquinolone-resistant Campylobacter infections in humans are a health hazard.

Included in the class of antimicrobials known as fluoroquinolones is enrofloxacin; ciprofloxacin is the comparable human drug in this class. Baytril, the trade name of enrofloxacin, is indicated for the control, in chickens, of mortality associated with Escherichia coli (E.coli) and in turkeys, of mortality associated with E.coli and Pasterella multocida. Baytril is the product of Bayer Corp., Shawnee Mission, KS, which requested a hearing regarding CVM's proposed withdrawal of approval.

The Final Decision of the FDA Commissioner, dated July 27, 2005, ordered the approval for NADA 140-828, be withdrawn pursuant to § 512(e)(1)(B) of the Food Drug and Cosmetic Act.  The order is effective September 12, 2005.

Selected Food and Drug Administration (FDA) documents addressing the enrofloxacin for poultry withdrawal are posted on this page. For all of the documents on this withdrawal please visit Dockets and search for Docket No. 2000N-1571, Enrofloxacin for Poultry: Withdrawal of Approval of Bayer Corporation’s New Animal Drug Application (NADA) 140-828 (Baytril).

CVM Updates/FDA News Releases

Page Last Updated: 07/14/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.